|
🐜
|
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
228 auth.
L. Paz-Ares,
M. Dvorkin,
Yuanbin Chen,
N. Reinmuth,
K. Hotta,
D. Trukhin,
G. Statsenko,
M. Hochmair,
M. Özgüroğlu,
J. Ji,
O. Voitko,
A. Poltoratskiy,
Santiago Ponce,
F. Verderame,
L. Havel,
...
I. Bondarenko,
A. Każarnowicz,
G. Losonczy,
N. Conev,
J. Armstrong,
N. Byrne,
N. Shire,
Haiyi Jiang,
J. Goldman,
E. Batagelj,
Ignacio Casarini,
A. V. Pastor,
S. Sena,
J. Zarbá,
O. Burghuber,
S. Hartl,
B. Lamprecht,
M. Studnicka,
L. Schlittler,
Fabricio Augusto Martinelli de Oliveira,
A. Calabrich,
G. Girotto,
P. Reis,
Carlo Gorini,
Peo Rafael Martins De Marchi,
C. Baldotto,
C. Sette,
M. Zukin,
A. Dudov,
R. Ilieva,
K. Koynov,
R. Krasteva,
I. Tonev,
S. Valev,
V. Venkova,
M. Bi,
Chengshui Chen,
Yuan Chen,
Zhendong Chen,
J. Fang,
Jifeng Feng,
Zhigang Han,
Jie Hu,
Yi Hu,
Wei Li,
Zongan Liang,
Zhong Lin,
R. Ma,
Shenglin Ma,
K. Nan,
Y. Shu,
Kai Wang,
Mengzhao Wang,
Gang Wu,
N. Yang,
Zhi-Xiong Yang,
He-long Zhang,
Wei Zhang,
Jun Zhao,
Yanqiu Zhao,
Caicun Zhou,
Jianying Zhou,
Xiang-dong Zhou,
V. Kolek,
L. Koubková,
J. Roubec,
J. Skřičková,
M. Zemanova,
C. Chouaid,
W. Hilgers,
H. Léna,
D. Moro-Sibilot,
G. Robinet,
P. Souquet,
J. Alt,
H. Bischoff,
C. Grohé,
E. Laack,
S. Lang,
J. Panse,
C. Schulz,
K. Bogos,
E. Csánky,
Anea Fülöp,
Z. Horváth,
Judit Kósa,
I. Laczó,
G. Pajkos,
Z. Pápai,
Zsolt Pápai Székely,
V. Sárosi,
A. Somfay,
É. Ezer,
Anás Telekes,
J. Bar,
M. Gottfried,
N. Heching,
Alona Zer Kuch,
R. Bartolucci,
A. Bettini,
A. Delmonte,
M. Garassino,
M. Minelli,
F. Roila,
S. Atagi,
K. Azuma,
H. Goto,
K. Goto,
Yu Hara,
H. Hayashi,
T. Hida,
Kenya Kanazawa,
S. Kanda,
Y. H. Kim,
S. Kuyama,
T. Maeda,
M. Morise,
Y. Nakahara,
M. Nishio,
N. Nogami,
I. Okamoto,
H. Saito,
M. Shinoda,
S. Umemura,
T. Yoshida,
N. Claessens,
R. Cornelissen,
Lizza Heniks,
Jeroen Hiltermann,
E. Smit,
A. J. S. D. Brekel,
D. Kowalski,
S. Mańdziuk,
Robert Mróz,
M. Wojtukiewicz,
T. Ciuleanu,
D. Ganea,
A. Ungureanu,
A. Luft,
V. Moiseenko,
D. Sakaeva,
A. Smolin,
Alexander Vasilyev,
L. Vladimirova,
Igor Anasina,
J. Chovanec,
P. Demo,
R. Godal,
P. Kasan,
M. Stresko,
M. Urda,
E. Cho,
Joo‐Hang Kim,
Sang-We Kim,
Gyeong-Won Lee,
Jong-Seok Lee,
K. Lee,
K. Lee,
Yun-Gyoo Lee,
M. Molla,
M. D. Gómez,
J. I. D. Mingorance,
D. Casado,
M. L. Brea,
M. M. Tarruella,
T. M. Bueno,
A. N. Mendivil,
Luis Paz-Ares Rodríguez,
S. P. Aix,
M. Campelo,
G. Chang,
Yen-Hsun Chen,
C. Chiu,
T. Hsia,
Kang-Yun Lee,
Chien-Te Li,
Chin-Chou Wang,
Yu-Feng Wei,
Shang‐Yin Wu,
A. Alacacıoğlu,
I. Çiçin,
A. Demirkazık,
M. Erman,
T. Göksel,
H. Adamchuk,
O. Kolesnik,
A. Kryzhanivska,
Y. Ostapenko,
S. Shevnia,
Y. Shparyk,
G. Ursol,
N. Voitko,
I. Vynnychenko,
S. Babu,
A. Chiang,
W. Chua,
S. Dakhil,
A. Dowlati,
Basir Haque,
Rodney Jamil,
J. Knoble,
Shailena Lakhanpal,
Kailhong Mi,
P. Nikolinakos,
S. Powell,
H. Ross,
E. Schaefer,
J. Schneider,
Joseph E. Spahr,
D. Spigel,
J. Stilwill,
C. Sumey,
Michael Williamson
|
10 |
2019 |
10
🐜
|
|
🐜
|
Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11).
34 auth.
Yunpeng Yang,
Zhehai Wang,
J. Fang,
Qitao Yu,
B. Han,
S. Cang,
Gongyan Chen,
X. Mei,
Zhi-Xiong Yang,
R. Ma,
M. Bi,
X. Ren,
Jianying Zhou,
Baolan Li,
Yong Song,
...
Jifeng Feng,
Juan Li,
Zhiyong He,
R. Zhou,
Wei-min Li,
You Lu,
Yingyi Wang,
Lijun Wang,
N. Yang,
Yan Zhang,
Zhuang Yu,
Yanqiu Zhao,
C. Xie,
Ying Cheng,
Hui Zhou,
Shuyan Wang,
Donglei Zhu,
W. Zhang,
Li Zhang
|
7 |
2020 |
7
🐜
|
|
🐜
|
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Non-squamous NSCLC in the Phase III ORIENT-11 Study.
31 auth.
Yunpeng Yang,
Jiya Sun,
Zhehai Wang,
J. Fang,
Qitao Yu,
B. Han,
S. Cang,
Gongyan Chen,
X. Mei,
Zhi-Xiong Yang,
R. Ma,
M. Bi,
X. Ren,
Jianying Zhou,
Baolan Li,
...
Yong Song,
Jifeng Feng,
Juan Li,
Zhiyong He,
R. Zhou,
Wei-min Li,
You Lu,
Hui Zhou,
Shuyan Wang,
Luyao Sun,
Oscar Puig,
C. Mancao,
B. Peng,
W. Fang,
Wei Xu,
Li Zhang
|
6 |
2021 |
6
🐜
|
|
🐜
|
Metformin induces apoptosis via a mitochondria-mediated pathway in human breast cancer cells in vitro
9 auth.
Zhenyuan Gao,
Zhe Liu,
M. Bi,
Jingjing Zhang,
Zhengquan Han,
Xiao Han,
...
Hong-Ya Wang,
G. Sun,
Hao Liu
|
6 |
2016 |
6
🐜
|
|
🐜
|
Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study
13 auth.
Yuankai Shi,
Q. Cai,
Yu Jiang,
Gang Huang,
M. Bi,
Baocheng Wang,
Yuhong Zhou,
Guo-wen Wang,
H. Ying,
Zhiwei Tao,
...
C. Shi,
Qian-chen Guo,
Chao Gao
|
4 |
2020 |
4
🐜
|
|
🐜
|
Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial
18 auth.
T. Chu,
Jun Lu,
M. Bi,
He-long Zhang,
W. Zhuang,
Yan Yu,
Jianhua Shi,
Zhendong Chen,
Xiaochun Zhang,
Q. Guo,
...
Quan Liu,
Huijuan Wu,
J. Fang,
Yi Hu,
Xiuwen Wang,
C. Han,
Kai Li,
B. Han
|
4 |
2021 |
4
🐜
|
|
🐜
|
SRPX2 promotes cell migration and invasion via FAK dependent pathway in pancreatic cancer.
7 auth.
Zhenyuan Gao,
Jingjing Zhang,
M. Bi,
Xiao Han,
Zhengquan Han,
Hong-Ya Wang,
...
Y. Ou
|
4 |
2015 |
4
🐜
|
|
🐬
|
Downregulation of NEAT1 Suppresses Cell Proliferation, Migration, and Invasion in NSCLC Via Sponging miR-153-3p.
Lun Zhao,
M. Bi,
Haoran Zhang,
Mohan Shi
|
4 |
2020 |
4
🐬
|
|
🐜
|
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial
76 auth.
Yuankai Shi,
K. Lei,
Yuming Jia,
Bingqiang Ni,
Zhiyong He,
M. Bi,
Xicheng Wang,
Jianhua Shi,
Ming Zhou,
Qiang Sun,
Guolei Wang,
Dongji Chen,
Y. Shu,
Lianke Liu,
Zhongliang Guo,
...
Yong Liu,
Junquan Yang,
Ke Wang,
Ke Xiao,
Lin Wu,
T. Yi,
Debin Sun,
Ma-fei Kang,
Tianjiang Ma,
Y. Mao,
Jinsheng Shi,
T. Tang,
Yan Wang,
P. Xing,
D. Lv,
W. Liao,
Zhiguo Luo,
Bin Wang,
Xiaohong Wu,
Xiao-Li Zhu,
Shuhua Han,
Q. Guo,
Rongyu Liu,
Zhiwei Lu,
Jianyong Zhang,
J. Fang,
Changlu Hu,
Yinghua Ji,
Guolong Liu,
Hong Lu,
Dedong Wu,
Junhong Zhang,
Shuyang Zhu,
Zheng Liu,
W. Qiu,
F. Ye,
Yan Yu,
Yanqiu Zhao,
Q. Zheng,
Jun Chen,
Z. Pan,
Yiping Zhang,
Wen-fei Lian,
B. Jiang,
B. Qiu,
Guojun Zhang,
Hua Zhang,
Yanju Chen,
Yuan Chen,
H. Duan,
Manxiang Li,
Shengming Liu,
Lijun Ma,
H. Pan,
Xia Yuan,
Xu Yuan,
Yulong Zheng,
E. Gao,
Li Zhao,
Shumin Wang,
Can Wu
|
4 |
2021 |
4
🐜
|
|
🐜
|
Ef fi cacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/ Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study
55 auth.
Yuankai Shi,
Shiman Wu,
Kenneth K. Wang,
S. Cang,
W. Yao,
Yun Fan,
Lin Wu,
Meijuan Huang,
Xingya Li,
Yueyin Pan,
Zhi-Xiong Yang,
B. Zhu,
Gongyan Chen,
Jianhua Shi,
Meili Sun,
...
J. Fang,
Lijun Wang,
Zhaohong Chen,
Chunling Liu,
Jing-zhang Li,
Jiwei Liu,
Sheng-hua Sun,
Yanqiu Zhao,
Yanzhen Guo,
Zili Meng,
Zhe-feng Liu,
Zhigang Han,
Hong Lu,
Aa,
R. Ma,
Shengxiang Hu,
Guofang Zhao,
Zheng Liu,
ee,
C. Xie,
Ff,
D. Zhong,
Huimin Zhao,
Huiqing Yu,
Longzhen Zhang,
jj,
M. Bi,
Shanyong Yi,
Shu-Yan Guo,
T. Yi,
Wen Li,
oo,
Yingcheng Lin,
Y. Shu,
Zhendong Chen,
Zhongliang Guo,
M. Greco,
tt,
T. Wang,
H. Shen
|
3 |
2022 |
3
🐜
|
